11:54 AM EST - Trillium Therapeutics Inc. : Announced today that new preclinical data and a patient case study for its CD47-blocking agent, TTI-621 (SIRPa-IgG1 Fc), were presented at the EORTC CLTF meeting in London, England over the weekend. Trillium Therapeutics Inc.
shares T.TRIL are trading up $0.23 at $7.91.
